IRIS
PINATO, David James
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.213
AS - Asia 5.794
NA - Nord America 5.116
SA - Sud America 788
AF - Africa 339
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 18.261
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.905
RU - Federazione Russa 2.466
SG - Singapore 2.289
IE - Irlanda 1.239
HK - Hong Kong 1.104
CN - Cina 1.015
BR - Brasile 587
VN - Vietnam 567
IT - Italia 443
DE - Germania 429
FR - Francia 412
SE - Svezia 369
UA - Ucraina 215
BJ - Benin 206
GB - Regno Unito 180
IN - India 171
KR - Corea 150
CA - Canada 104
FI - Finlandia 98
AT - Austria 96
MX - Messico 78
AR - Argentina 72
BD - Bangladesh 71
JP - Giappone 69
PL - Polonia 58
ES - Italia 52
ID - Indonesia 51
ZA - Sudafrica 51
NL - Olanda 45
IQ - Iraq 44
TR - Turchia 43
CO - Colombia 32
IR - Iran 32
LT - Lituania 29
MA - Marocco 26
PK - Pakistan 26
EC - Ecuador 25
PH - Filippine 25
VE - Venezuela 20
SA - Arabia Saudita 18
CL - Cile 17
CZ - Repubblica Ceca 17
UZ - Uzbekistan 15
PY - Paraguay 14
BE - Belgio 13
CH - Svizzera 13
OM - Oman 11
AE - Emirati Arabi Uniti 9
EG - Egitto 9
JO - Giordania 9
TN - Tunisia 9
KE - Kenya 8
ET - Etiopia 7
IL - Israele 7
NP - Nepal 7
PE - Perù 7
UY - Uruguay 7
BO - Bolivia 6
DO - Repubblica Dominicana 6
DZ - Algeria 6
KZ - Kazakistan 6
MY - Malesia 6
RS - Serbia 6
TW - Taiwan 6
BG - Bulgaria 5
JM - Giamaica 5
LB - Libano 5
PS - Palestinian Territory 5
PT - Portogallo 5
SN - Senegal 5
AU - Australia 4
AZ - Azerbaigian 4
BH - Bahrain 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
CR - Costa Rica 3
EU - Europa 3
HN - Honduras 3
HU - Ungheria 3
KG - Kirghizistan 3
LV - Lettonia 3
MN - Mongolia 3
SY - Repubblica araba siriana 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BF - Burkina Faso 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CY - Cipro 2
GT - Guatemala 2
KH - Cambogia 2
LI - Liechtenstein 2
RO - Romania 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
XK - ???statistics.table.value.countryCode.XK??? 2
AI - Anguilla 1
BB - Barbados 1
BW - Botswana 1
Totale 18.238
Salva come PNG Salva come JPEG
Città #
Dublin 1.236
Hong Kong 1.094
San Jose 991
Singapore 932
Ashburn 558
Moscow 296
Beijing 294
Lauterbourg 246
Los Angeles 236
Cotonou 206
Ho Chi Minh City 159
Lawrence 149
Princeton 149
Jacksonville 142
Wilmington 139
Seoul 137
Hanoi 136
Buffalo 134
San Mateo 125
Chandler 113
Santa Clara 104
New York 101
Falkenstein 76
São Paulo 71
Dallas 67
Novara 67
Nuremberg 66
Helsinki 58
Orem 58
Tokyo 58
Chennai 55
Dearborn 55
Frankfurt am Main 55
Brooklyn 52
Vienna 51
Council Bluffs 49
Redondo Beach 48
Piemonte 46
Warsaw 43
Munich 41
Chicago 40
Denver 39
London 39
Mexico City 39
Tianjin 39
Ann Arbor 38
Assago 36
Haiphong 34
Johannesburg 34
Stockholm 34
Montreal 33
Milan 32
Toronto 32
Da Nang 30
Guangzhou 30
Boardman 28
Houston 28
Phoenix 28
Amsterdam 27
Boston 27
Poplar 27
Turin 27
Atlanta 25
Manchester 25
Vercelli 25
Hangzhou 24
Andover 23
Jakarta 22
Mumbai 22
Shanghai 22
Strasbourg 22
Ankara 18
Bremen 18
Shenzhen 18
Rome 16
Zanjan 16
San Francisco 15
Dhaka 14
Norwalk 14
Roubaix 14
Tashkent 13
Baghdad 12
Brasília 12
Brussels 12
Pleasantville 12
Turku 12
Belo Horizonte 11
Manila 11
New Delhi 11
Rio de Janeiro 11
Woodbridge 11
City of London 10
Hải Dương 10
Istanbul 10
Ribeirão Preto 10
Seattle 10
West Jordan 10
Cape Town 9
Hefei 9
Medellín 9
Totale 9.982
Salva come PNG Salva come JPEG
Nome #
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease 180
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study 155
Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19 140
Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study 137
Validation of the Hepatoma Arterial Embolization Prognostic Score in European and Asian Populations and Proposed Modification. 134
L’impatto del Long COVID è stato minore nella terza ondata della pandemia rispetto alla prima ondata in una popolazione italiana di 324 pazienti. 133
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib 133
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma 132
Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma 131
Time-Dependent COVID-19 Mortality in Patients with Cancer: An Updated Analysis of the OnCovid Registry 130
Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: A multi-center comparative study 129
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 121
Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of patients with cancer who recovered from SARS-Cov-2 infection: results from the OnCovid registry. 120
Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe 118
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 117
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 116
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: The OnCovid Inflammatory Score 116
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 112
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma 111
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 111
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study 107
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 107
Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. 105
HBV AND LYMPHOMAGENESIS: NOVEL INSIGHTS INTO AN OCCULT RELATIONSHIP 103
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 102
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study 102
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 99
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study 98
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries 94
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 94
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study 93
The albumin–bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development 92
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis 91
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer 91
Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship 90
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 90
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study 89
Antibiotic therapy and outcome from immune-checkpoint inhibitors 89
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter? 87
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma 87
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 87
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 87
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 86
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry 86
Immunotherapy vs Best Supportive Care for Patients with Hepatocellular Cancer with Child-Pugh B Dysfunction 86
A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers 85
T-cell mediated responses against alpha-foetoprotein in hepatocellular carcinoma: Relationship with hepatitis C virus infection, tumour phenotype and patients’ survival 84
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 83
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 83
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma 82
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors 81
Advanced age influences the dynamic changes in circulating C-reactive protein following injury 80
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 80
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 79
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 79
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 78
Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma 78
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey 78
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 77
Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death 77
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 77
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice 76
A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: The prognostic nutritional index (PNI) 76
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 76
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy 76
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 76
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 75
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 75
Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients 75
Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis 75
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 74
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 74
Assessing the impact of COVID-19 on liver cancer management (CERO-19) 74
Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy 74
Acceleration of interstitial lung disease induced by raltitrexed 74
A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC 73
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis 73
Back from the brink: EGFR inhibition in gastroesophageal cancer 73
A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI) 73
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors 73
Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma 72
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 72
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials 72
Biliary tract cancers: Molecular heterogeneity and new treatment options 72
Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy 72
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 72
The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma 71
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 71
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials 70
Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison 70
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 70
Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal 69
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? 69
INTERLEUKIN-6 POLYMORPHISMS AND GENDER: RELATIONSHIP WITH THE OCCURRENCE OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH END-STAGE LIVER DISEASE 69
The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application 68
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach 68
An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: Correlation with tumour phenotype and survival outcomes 68
Immunotherapies for hepatocellular carcinoma 67
The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma 67
An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma 67
Totale 9.010
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.446
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.446
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021254 0 0 0 0 0 0 0 0 0 113 128 13
2021/2022799 27 2 174 71 46 6 24 21 68 63 126 171
2022/20231.810 217 43 77 6 51 106 43 79 1.132 5 27 24
2023/20241.084 136 46 82 33 209 14 222 15 4 39 56 228
2024/20253.885 45 26 204 19 36 331 391 346 904 590 261 732
2025/202610.222 548 499 678 1.060 1.303 833 1.964 1.777 881 679 0 0
Totale 18.630